Clinical Trial Update: Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating the combination of nivolumab with ASTX727 (decitabine/cedazuridine) in relapsed or refractory B-cell lymphomas, currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Diffuse Large B-cell Lymphoma
• Hodgkin Lymphoma

Drugs mentioned

• ASTX727 (decitabine/cedazuridine) (decitabine/cedazuridine)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Status: RECRUITING